Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

Advances in RA treatment require improved understanding of patient-specific therapy appropriateness, focusing on disease pathogenesis and heterogeneity. Current RA treatment algorithms lack biomarkers ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

RA is an autoimmune disease where the immune system mistakenly attacks the lining of joints, causing inflammation and potential joint damage. Treatment goals for RA include reducing inflammation and ...

Treatments and outcomes for rheumatoid arthritis (RA) have made major advances in the last decade. Earlier diagnoses, better treatment strategies, and improvements in disease modifying anti-rheumatic ...

The results of research by scientists at Trinity College Dublin and St. Vincent’s University Hospital offer new insights into the cellular and genetic features of joint inflammation in rheumatoid ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.

A new study, completed by researchers at Columbia University in New York and Brigham and Women’s Hospital in Boston, suggests that some drugs used to treat rheumatoid arthritis (RA) may also help ...